title: Rho kinase as a target for cerebral vascular disorders.
abstract: The development of novel pharmaceutical treatments for disorders of the cerebral vasculature is a serious unmet medical need. These vascular disorders are typified by a disruption in the delicate Rho signaling equilibrium within the blood vessel wall. In particular, Rho kinase overactivation in the smooth muscle and endothelial layers of the vessel wall results in cytoskeletal modifications that lead to reduced vascular integrity and abnormal vascular growth. Rho kinase is thus a promising target for the treatment of cerebral vascular disorders. Indeed, preclinical studies indicate that Rho kinase inhibition may reduce the formation/growth/rupture of both intracranial aneurysms and cerebral cavernous malformations.
authors.affiliation: BioAxone BioSciences, Inc., 10 Rogers Street, Suite 101, Kendall Square, Cambridge, MA 02142, USA.|Laboratory of Molecular Physiology, National Heart, Lung & Blood Institute, Bethesda, MD 20892, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Bond
authors.affiliation: Laboratory of Molecular Physiology, National Heart, Lung & Blood Institute, Bethesda, MD 20892, USA.
authors.forename: James R
authors.initials: JR
authors.lastname: Sellers
authors.affiliation: BioAxone BioSciences, Inc., 10 Rogers Street, Suite 101, Kendall Square, Cambridge, MA 02142, USA.
authors.forename: Lisa
authors.initials: L
authors.lastname: McKerracher
mesh_terms: D000818:Animals; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D054460:rho-Associated Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; D054460:rho-Associated Kinases